Fairmount Funds Management LLC - 28 Apr 2025 SCHEDULE 13D Report for Jade Biosciences, Inc. Common Stock, $0.0001 par value (JBIO)

Filing Manager
Fairmount Funds Management LLC
Reporting Manager
Fairmount Funds Management LLC
Security
Jade Biosciences, Inc. Common Stock, $0.0001 par value
Symbol
JBIO
Shares outstanding
36,264,912 shares
Disclosed Ownership
7,249,356 shares
Ownership
20%
Form type
SCHEDULE 13D
Filing time
01 May 2025, 18:31:59 UTC
Date of event
28 Apr 2025
Next filing
08 Oct 2025
SEC
View on sec.gov

Quoteable Key Fact

"Fairmount Funds Management LLC disclosed 20% ownership in Jade Biosciences, Inc. Common Stock, $0.0001 par value (JBIO) on 28 Apr 2025."

Quick Takeaways

  • Fairmount Funds Management LLC filed SCHEDULE 13D for Jade Biosciences, Inc. Common Stock, $0.0001 par value (JBIO).
  • Disclosed ownership: 20%.
  • Date of event: 28 Apr 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 01 May 2025, 18:31.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Fairmount Funds Management LLC 20% 7,249,356 0 7,249,356 /s/ Peter Harwin Peter Harwin, Managing Member 0001802528
Fairmount Healthcare Fund II L.P. 13% 4,592,551 0 4,592,551 /s/ Peter Harwin Peter Harwin, Managing Member 0001769651
Fairmount Healthcare Co-Invest IV L.P. 8.2% 2,655,817 0 2,655,817 /s/ Peter Harwin Peter Harwin, Managing Member 0002042283
Peter Evan Harwin 20% 7,249,356 0 7,249,356 /s/ Peter Harwin Peter Harwin 0001663607
Tomas Kiselak 20% 7,249,356 0 7,249,356 /s/ Tomas Kiselak Tomas Kiselak 0001830177